CorVel Corp. (NASDAQ:CRVL – Get Free Report) insider Maxim Shishin sold 2,250 shares of the stock in a transaction that occurred on Friday, June 12th. The shares were sold at an average price of $60.59, for a total transaction of $136,327.50. Following the transaction, the insider directly owned 7,050 shares of the company’s stock, valued at $427,159.50. This represents a 24.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
CorVel Stock Down 2.6%
CorVel stock opened at $58.14 on Thursday. CorVel Corp. has a twelve month low of $44.83 and a twelve month high of $105.50. The firm has a 50 day moving average price of $58.27 and a 200-day moving average price of $59.86. The company has a market capitalization of $2.95 billion, a P/E ratio of 27.17 and a beta of 0.99.
CorVel (NASDAQ:CRVL – Get Free Report) last released its earnings results on Tuesday, May 19th. The business services provider reported $0.61 earnings per share for the quarter. CorVel had a net margin of 11.51% and a return on equity of 29.92%. The firm had revenue of $248.55 million during the quarter.
Institutional Inflows and Outflows
Analyst Upgrades and Downgrades
CRVL has been the subject of several analyst reports. Wall Street Zen raised shares of CorVel from a “hold” rating to a “buy” rating in a report on Saturday, May 30th. Weiss Ratings downgraded shares of CorVel from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, April 6th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has a consensus rating of “Sell”.
Get Our Latest Report on CorVel
About CorVel
CorVel Corporation (NASDAQ: CRVL) is a technology-driven provider of workers’ compensation, liability, and specialty risk management solutions. The company develops and deploys software and data analytics tools to streamline claims administration, medical cost containment, prescription drug management, and provider network access. CorVel’s integrated platform connects employers, insurers, healthcare providers, and injured workers, aiming to improve outcomes and control costs through process automation and real-time decision support.
The company’s product suite includes claims lifecycle management, bill review and negotiation, virtual care and telehealth services, pharmacy benefit management, and independent medical examinations (IMEs).
See Also
- Five stocks we like better than CorVel
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Receive News & Ratings for CorVel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorVel and related companies with MarketBeat.com's FREE daily email newsletter.
